title: In vivo action of a new octadecaneuropeptide antagonist on neuropeptide Y and corticotropin-releasing hormone mRNA levels in rat.
abstract: It has been reported that several of the effects induced by an octadecaneuropeptide (ODN), derived from an 86-amino-acid polypeptide termed diazepam-binding inhibitor, could be mediated by activation of a metabotropic receptor. In order to investigate the role and mechanism of action of ODN in the regulation of corticotropin-releasing factor (CRH) and neuropeptide Y (NPY) expression in the paraventricular nucleus and arcuate nucleus, respectively, we studied the effects of the acute intracerebroventricular administration of ODN (2 microg/rat) and the ODN antagonist to metabotropic receptor, cyclo(1-8)[Dleu5]OP (20 microg/rat), on the gene expression of the two neuropeptides in castrated male rat. ODN administration resulted in a 45% increase in CRH mRNA expression, an effect which was reversed by cyclo(1-8)[Dleu5]OP. When cyclo(1-8)[Dleu5]OP was administered alone, it induced a 19% decrease in CRH mRNA levels. ODN administration induced a 17% decrease in NPY mRNA expression while cyclo(1-8)[Dleu5]OP increased by 21% the hybridization signal. The administration of both ODN and ODN antagonist completely abolished the depressing effect of ODN on NPY mRNA. These data suggest that the effects of ODN on CRH and NPY mRNA might be mediated by interaction with metabotropic receptors. Moreover, since cyclo(1-8)[Dleu5]OP can by itself influence the expression of two peptide mRNAs, it might be suggested that ODN is exerting a tonic influence on NPY and CRH neurons.
authors.affiliation: European Institute for Peptide Research (IFRMP 23), Laboratory of Cellular and Molecular Neuroendocrinology, INSERM U413, UA CNRS, University of Rouen, Mont-Saint-Aignan, France.
authors.forename: V
authors.initials: V
authors.lastname: Compère
authors.forename: S
authors.initials: S
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Leprince
authors.forename: M C
authors.initials: MC
authors.lastname: Tonon
authors.forename: H
authors.initials: H
authors.lastname: Vaudry
authors.forename: G
authors.initials: G
authors.lastname: Pelletier
mesh_terms: D000818:Animals; D003346:Corticotropin-Releasing Hormone / Q000096:biosynthesis* / Q000235:genetics; D026261:Diazepam Binding Inhibitor; D005786:Gene Expression Regulation / Q000187:drug effects*; D017403:In Situ Hybridization; D008297:Male; D009478:Neuropeptide Y / Q000096:biosynthesis* / Q000235:genetics; D009479:Neuropeptides / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009919:Orchiectomy; D010446:Peptide Fragments; D010456:Peptides, Cyclic / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D026261:Diazepam Binding Inhibitor; D009478:Neuropeptide Y; D009479:Neuropeptides; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D012333:RNA, Messenger; D018094:Receptors, Metabotropic Glutamate; C487836:cyclo(Arg-Pro-Gly-Leu-Leu-Asp-Leu-Lys); C067529:diazepam binding inhibitor (33-50); D003346:Corticotropin-Releasing Hormone